TMU-35435 showed better inhibitory effects on total HDAC activity and isoform-specific HDAC activity, including HDAC6 activity, than did suberoylanilide hydroxamic acid (SAHA) [23], which was the first Food and Drug Administration (FDA)-approved HDACi for the treatment of lymphoma [24]. This evidence concerns the gene HDAC9 and lymphoma.